"In the treatment of non-small cell lung cancer (NSCLC), combined with NP, MVP chemotherapy, this product can be tried in ineffective therapy for advanced or recurrent NSCLC patients with other methods. In the treatment of non-Hodgkin's lymphoma (NHL), combined therapy with BACOP chemotherapy, also can be used in trial by chemotherapy or other methods in the treatment of advanced NHL of invalid patients. Registration Dossiers:non-clinical & clinical part, drug substance part and drug product part." "Highlights: 1, Promoting the concentration of chemotherapeutic drugs in tumor by four to six times 2,Owning synergistic effect by combining various chemotherapeutics 3,Promoting chemotherapeutic effect of late NSCLC and NHL significantly 4, Efficacy of Monotherapy in Malignant pleural effusion and ascites: 87% 5, Time to market: 2004 6, Originator: Beromun，Tasonermin® by Boehringer Ingelbeim Registration Dossiers:non-clinical & clinical part, drug substance part and drug product part."